UNION CITY, Calif., Oct. 26 /PRNewswire-FirstCall/ -- ABAXIS, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the fiscal quarter ended September 30, 2010.
Record quarterly highlights include:
Other quarterly highlights include:
Quarterly Results: For the fiscal quarter ended September 30, 2010, Abaxis reported revenues of $35.3 million, as compared with revenues of $30.3 million for the comparable period last year, an increase of 17 percent.
Revenues from instrument sales, which include chemistry analyzers, hematology instruments, coagulation analyzers and i-STAT analyzers, increased by an aggregate of $1.1 million, or 17 percent, over the same period last year. Total medical and veterinary instrument sales were 988 units, up 7 percent over the same period last year. Revenues from consumables, which include reagent discs, hematology reagent kits, coagulation cartridges, i-STAT cartridges and heartworm rapid tests, increased by an aggregate of $4.3 million, or 21 percent, over the same period last year.
The company reported net income of $3.7 million for the fiscal quarter ended September 30, 2010, compared to $3.2 million for the same period last year.
The company's effective tax rate in both three-month periods was 39 percent.
The company reported diluted net income per share of $0.17 (calculated based on 22,691,000 shares) for the three-month period ended September 30, 2010, compared to $0.14 per share (calculated based on 22,574,000 shares) for the same period last year.
Six-Month Results: For the six-month period ended September 30, 2010, Abaxis reported revenues of $70.2 million, as compared with revenues of $59.9 million for the comparable period last year, an increase of 17 percent.
Revenues from instrument sales increased by an aggregate of $2.1 million, or 17 percent, over the same period last year.
Total medical and veterinary instrument sales were 2,013 units, up 14 percent over the same period last year.
Revenues from consumables increased by an aggregate of $8.7 million, or 21 percent, over the same period last year.
The company reported net income of $7.3 million, compared to $7.0 million for the same period last year.
The company's effective tax rate in the six-month period ended September 30, 2010, was 39 percent, compared to 40 percent for the same period last year.
The company reported diluted net income per share of $0.32 (calculated based on 22,736,000 shares) for the six-month period ended September 30, 2010, compared to $0.31 per share (calculated based on 22,492,000 shares) for the same period last year.
Other Reported Information: Consumables revenues for the second quarter of fiscal 2011 were $25.3 million, up 21 percent over the $21.0 million reported for the same period last year. Total sales in the medical market for the second quarter of fiscal 2011 were $6.9 million, an increase of 8 percent compared to the same period last year. Medical sales worldwide, excluding sales to the U.S. government, during the second quarter of fiscal 2011 were $6.0 million, an increase of 7 percent compared to the same period last year. Total sales in the veterinary market for the second quarter of fiscal 2011 were $26.6 million, an increase of 23 percent compared to the same period last year. Veterinary reagent disc sales for the second quarter of fiscal 2011 were $14.8 million, an increase of 8 percent compared to the same period last year. Non-cash compensation expense recognized for share-based awards during the second quarter of fiscal 2011 was $1.1 million, compared to $1.4 million for the same period last year.
Clint Severson, chairman and chief executive officer of Abaxis, commented, "On a year-over-year basis revenues and net income for the quarter were both up 17%, led by a 23% increase in veterinary market revenues and a 38% increase in the number of Piccolo chemistry analyzer units sold in the medical market compared to last year's second quarter. We also achieved strong growth in consumables sales of 21% for the quarter. We are very pleased with the traction that we are gaining across our various markets. A strong focus on more effective sales and marketing efforts across all of our platforms has driven those gains."
Mr. Severson continued, "We are also very pleased that our razor/razorblade model continues to deliver outstanding results; 72% of our quarterly revenues are recurring and we believe that there is still headroom to drive this percentage higher in the coming years. In that regard, we believe that the substantial increase in the number of medical instruments placed in urgent care centers and in the internal medicine markets during the quarter will be solid contributors to our recurring revenue model. Additionally, we are dedicated to a strong and consistent research and development process to introduce new products that effectively diagnose conditions in both the veterinary and medical markets and that provide an additional cash flow stream to the medical professionals that rely on Abaxis technology. We also look forward to entering into the rapid testing market by taking full advantage of the lateral flow technology that we licensed. We believe there are exciting growth opportunities ahead in the coming years."
Conference CallAbaxis has scheduled a conference call to discuss its results at 4:15 p.m. Eastern Time on Tuesday, October 26, 2010. Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or can listen via a live Internet web cast, which is available in the Investor Relations section of the company's website at http://www.abaxis.com. A replay of the call is available by visiting http://www.abaxis.com for the next 30 days or by calling (877) 344-7529 or (412) 317-0088, access code 445369, through October 29, 2010. This press release is also available prior to and after the call via Abaxis' website or the Securities and Exchange Commission's website at http://www.sec.gov.
About AbaxisAbaxis develops, manufactures, markets and sells portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.
Use of Financial MeasuresTo supplement the financial statements presented in accordance with United States generally accepted accounting principles (GAAP), Abaxis uses operating income per share, a non-GAAP financial measure. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. For more information on this non-GAAP financial measure, refer to the table captioned "Operating Income Per Share" included at the end of this release. Abaxis defines operating income per share as operating income divided by the weighted average outstanding shares. Management uses this measure in comparing Abaxis' operating results with historical performance and believes it provides meaningful and comparable information to management and investors to assist in their review of Abaxis' performance relative to prior periods and its competitors.
This press release includes, and our conference call will include, statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance of new or planned product offerings, process improvements and product manufacturing quality and efficiencies in future production of our products. Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this press release or in Abaxis' conference call may be affected by risks and uncertainties, including, but not limited to, those related to the market acceptance of the company's products and the continuing development of its products, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with entering the human diagnostic market on a larger scale, risks related to the protection of the company's intellectual property or claims of infringement of intellectual property asserted by third parties, risks related to condition of the United States economy, risks involved in carrying of inventory and other risks detailed under "Risk Factors" in Abaxis' Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2010 and Abaxis' other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.
Financial Tables on Following PagesABAXIS, INC.Condensed Consolidated Statements of Income(in thousands, except per share data)(Unaudited)Three Months EndedSix Months EndedSeptember 30,September 30,2010200920102009Revenues
59,887Cost of revenues
35,006Operating expenses: Research and development
5,167 Sales and marketing
13,942 General and administrative
5,187Total operating expenses
24,296Income from operations
10,710Interest and other income (expense), net
806Income before income tax provision
11,516Income tax provision
,953Net income per share: Basic net income per share
.32 Diluted net income per share
.31Shares used in the calculation of net income per share: Weighted average common shares outstanding - basic
21,985 Weighted average common shares outstanding - diluted
22,492ABAXIS, INC.Condensed Consolidated Balance Sheets(Unaudited and in thousands)September 30,March 31,20102010Current assets:Cash and cash equivalents
19,067Prepaid expenses and other current assets
1,588Net deferred tax assets, current
3,773 Total current assets
36,319Property and equipment, net
15,544Intangible assets, net
4,600Net deferred tax assets, non-current
76 Total assets
7,816Current liabilities: Accounts payable
9,404 Accrued payroll and related expenses
5,615 Accrued taxes
400 Other accrued liabilities
1,256 Deferred revenue
1,157 Warranty reserve
1,183 Total current liabilities
19,015Non-current liabilities: Deferred rent
163 Deferred revenue
1,359 Warranty reserve
160 Total non-current liabilities
1,682Shareholders' equity: Common stock
125,050 Retained earnings
22,069 Total shareholders' equity
147,119 Total liabilities and shareholders' equity
7,816Operating Income Per Share(In thousands, except per share data)Three Months EndedSix Months EndedSeptember 30,September 30,2010200920102009Shares used in the calculation of operating income per share: Weighted average common shares outstanding - basic
21,985 Weighted average common shares outstanding - diluted
22,492Operating income per share - basic
.49Operating income per share - diluted
.48Revenues by Geographic Region(In thousands)Three Months EndedSix Months EndedSeptember 30,September 30,2010200920102009North America
59,887Revenues by Customer Group(In thousands)Three Months EndedSix Months EndedSeptember 30,September 30,2010200920102009Medical Market
|SOURCE Abaxis, Inc.|
Copyright©2010 PR Newswire.
All rights reserved